Literature DB >> 17079480

Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells.

Hee Kyu Lee1, Yong Seok Choi, Young Ae Park, Sunjoo Jeong.   

Abstract

Activated beta-catenin regulates the transcription of oncogenic target genes and is critical for tumorigenesis. Because nuclear functions are frequently coupled, we investigated whether it also has a role in alternative splicing of oncogenic genes. We showed that stabilized beta-catenin caused alternative splicing of estrogen receptor-beta pre-mRNA in colon cancer cells. To establish a direct role of beta-catenin in regulated splicing, we selected a high-affinity RNA aptamer that associated with beta-catenin in vivo. Nuclear localized aptamer inhibited beta-catenin-dependent transcription of cyclin D1 and c-myc in colon cancer cells; thus, cells stably expressing the aptamer exhibited cell cycle arrest and reduced tumor forming potential. Most significantly, the aptamer prevented the alternative splicing induced by stabilized beta-catenin. Taken together, our results establish that beta-catenin has an important role in both transcription and splicing, and that its action can be modulated by a high-affinity RNA aptamer. The RNA aptamer could be further developed as a specific inhibitor for cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079480     DOI: 10.1158/0008-5472.CAN-06-2526

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

2.  The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  RNA       Date:  2008-10-24       Impact factor: 4.942

3.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 4.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

Review 5.  Aptamers in Therapeutics.

Authors:  Abhishek Parashar
Journal:  J Clin Diagn Res       Date:  2016-06-01

Review 6.  Intracellular delivery of RNA-based therapeutics using aptamers.

Authors:  Kristina W Thiel; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2010-12

7.  microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer.

Authors:  Wei Chang Chen; Mao Song Lin; Yu Lan Ye; Heng Jun Gao; Zhen Yun Song; Xiao Ying Shen
Journal:  Exp Ther Med       Date:  2012-03-30       Impact factor: 2.447

8.  Duodenal gastric heterotopia, sporadic or fundic gland polyp-associated, frequently carries β-catenin mutation.

Authors:  Miku Nakagawa; Riko Kitazawa; Takeshi Kondo; Kosuke Ninomiya; Masayoshi Okita; Ryuma Haraguchi; Sohei Kitazawa
Journal:  Virchows Arch       Date:  2014-06-27       Impact factor: 4.064

Review 9.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

Review 10.  Alternative splicing within the Wnt signaling pathway: role in cancer development.

Authors:  B Sumithra; Urmila Saxena; Asim Bikas Das
Journal:  Cell Oncol (Dordr)       Date:  2016-01-13       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.